FindTrial
Sign In

Diagnostic and Prognostic Relevance of Routine Immunological Parameters in Patients on V-V ECMO: A Retrospective, Single-Center Analysis (ImmunECMO)

Diagnostic and Prognostic Relevance of Routine Immunological Parameters in Patients on V-V ECMO: A Retrospective, Single-Center Analysis (ImmunECMO) - ImmunECMO

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00039808
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-01-07
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory failure requiring veno-venous ECMO.

Interventions

Group 1: Retrospective analysis of all patients with acute respiratory failure treated with veno-venous ECMO (extracorporeal membrane oxygenation).

Sponsors

Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Bonn
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with acute respiratory failure of any cause, supported with veno-venous extracorporeal membrane oxygenation.

Exclusion criteria

Exclusion criteria: Age <18 years

Design outcomes

Primary

MeasureTime frame
Death before hospital discharge (all-cause mortality), days of survival—

Secondary

MeasureTime frame
length of stay (LoS in hospital and LoS in ICU), successful weaning from ECMO, duration of ECMO, days on mechanical ventilation (MV), successful weaning from MV, Sequential Organ Failure Assessment Score (SOFA), severity of illness (SAPS II, TISS-10) at admission, 24h after admission and at discharge from ICU, necessity of renal replacement therapy—

Countries

Germany

Contacts

Public ContactJens Poth

Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Bonn

jens.poth@ukbonn.de022828714379

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026